Cargando…

How to use COVID-19 antiviral drugs in patients with chronic kidney disease

Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid), Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus Disease (COVID)-19. Although chronic kidney disease is a highly prevalent risk factor for severe and fatal COVID-19, most c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kale, Ajinath, Shelke, Vishwadeep, Dagar, Neha, Anders, Hans-Joachim, Gaikwad, Anil Bhanudas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947246/ https://www.ncbi.nlm.nih.gov/pubmed/36843922 http://dx.doi.org/10.3389/fphar.2023.1053814

Ejemplares similares

Voclosporin: Unique Chemistry, Pharmacology and Toxicity Profile, and Possible Options for Implementation into the Management of Lupus Nephritis
por: Kale, Ajinath, et al.
Publicado: (2023)

Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery
por: Li, Xinlei, et al.
Publicado: (2021)

Editorial: Antiviral drugs and vaccines against important human respiratory viruses
por: Yang, Minghui, et al.
Publicado: (2022)

The Potential of Antiviral Peptides as COVID-19 Therapeutics
por: Mahendran, Arun Suria Karnan, et al.
Publicado: (2020)

An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
por: Indari, Omkar, et al.
Publicado: (2021)

Editorial: Emerging and old viral diseases: Antiviral drug discovery from medicinal plants
por: Rahmatullah, Mohammed, et al.
Publicado: (2022)

Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection
por: Ayatollahi, Seyed Abdulmajid, et al.
Publicado: (2021)

Effect of polymorphisms in drug metabolism and transportation on plasma concentration of atorvastatin and its metabolites in patients with chronic kidney disease
por: Jiang, Zebin, et al.
Publicado: (2023)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
por: Canonico, Mario Enrico, et al.
Publicado: (2022)

Neuropsychiatric Disorders in Chronic Kidney Disease
por: Simões e Silva, Ana Cristina, et al.
Publicado: (2019)

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
por: Lee, Fei Yee, et al.
Publicado: (2022)

The Intestinal Microbiota and Metabolites in the Gut-Kidney-Heart Axis of Chronic Kidney Disease
por: Huang, Yinghui, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses’ infections
por: Ghrieb, Zineb, et al.
Publicado: (2023)

Editorial: The gut-kidney axis: A potential drug target for treating kidney diseases
por: Chen, Jianping, et al.
Publicado: (2022)

Immunosuppressant drugs and quality-of-life outcomes in kidney transplant recipients: An international cohort study (EU-TRAIN)
por: Girardin, François R., et al.
Publicado: (2023)

Evaluation of the effect of direct-acting antiviral agents on melatonin level and lipid peroxidation in chronic hepatitis C patients
por: El-Mahdy, Nageh Ahmed, et al.
Publicado: (2023)

How to Assess Drugs in the Treatment of Acute Bipolar Mania?
por: Bourin, Michel, et al.
Publicado: (2013)

How do antimalarial drugs reach their intracellular targets?
por: Basore, Katherine, et al.
Publicado: (2015)

Kidney Organoid and Microphysiological Kidney Chip Models to Accelerate Drug Development and Reduce Animal Testing
por: Chen, Wei-Yang, et al.
Publicado: (2021)

The role of drug transporters in the kidney: lessons from tenofovir
por: Moss, Darren M., et al.
Publicado: (2014)

The Use of Chinese Yang/Qi-Invigorating Tonic Botanical Drugs/Herbal Formulations in Ameliorating Chronic Kidney Disease by Enhancing Mitochondrial Function
por: Tian, Jiayi, et al.
Publicado: (2021)

Editorial: Plant products for antiviral therapeutics
por: Mandal, Anirban, et al.
Publicado: (2022)

Mitochondrial Targeting of Herbal Medicine in Chronic Kidney Disease
por: Li, Qing, et al.
Publicado: (2021)

Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease
por: Yan, Zhonghong, et al.
Publicado: (2021)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis
por: Zhou, Yu, et al.
Publicado: (2022)

Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery
por: Zakharova, Maria Yu., et al.
Publicado: (2021)

The Signaling Pathways, and Therapeutic Targets of Antiviral Agents: Focusing on the Antiviral Approaches and Clinical Perspectives of Anthocyanins in the Management of Viral Diseases
por: Mohammadi Pour, Pardis, et al.
Publicado: (2019)

Corrigendum: The role of drug transporters in the kidney: lessons from tenofovir
por: Moss, Darren M.
Publicado: (2015)

Neuropsychiatric disorders in chronic hepatitis C patients after receiving interferon or direct-acting antivirals: a nationwide cohort study
por: Fang, Yu, et al.
Publicado: (2023)

Bilirubin: An Endogenous Molecule with Antiviral Activity in vitro
por: Santangelo, Rosaria, et al.
Publicado: (2012)

Mechanisms and Efficacy of Chinese Herbal Medicines in Chronic Kidney Disease
por: Zhao, Mingming, et al.
Publicado: (2021)

Editorial: Applications of Herbal Medicine to Control Chronic Kidney Disease
por: Chen, Jianping, et al.
Publicado: (2021)

Aryl Hydrocarbon Receptor Mechanisms Affecting Chronic Kidney Disease
por: Curran, Colleen S., et al.
Publicado: (2022)

The controversy of klotho as a potential biomarker in chronic kidney disease
por: Yu, Li-Xia, et al.
Publicado: (2022)

Hypertension in chronic kidney disease: What lies behind the scene
por: Ameer, Omar Z.
Publicado: (2022)

Thymoquinone’s Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge
por: Abdelrahim, Maen, et al.
Publicado: (2022)

The role of the SGK3/TOPK signaling pathway in the transition from acute kidney injury to chronic kidney disease
por: Shu, Huapan, et al.
Publicado: (2023)

Potentially inappropriate medication including drug-drug interaction and the risk of frequent falling, hospital admission, and death in older adults - results of a large cohort study (getABI)
por: Reinhild Haerig, Theresa, et al.
Publicado: (2023)

Drug-induced kidney injury in Chinese critically ill pediatric patients
por: Hu, Biwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ptftu2h9f2i05qjuei54bm7oi3